move show deliveri
bottom line move show-m statu deliveri state
expect stock respond kind sever stop-and-go quarter
deliveri realli good revenu organ
surpass street deliv highest growth rate sinc ep
pro forma ahead street oper
fx tax relat free cash flow improv
reiter outperform
strength quarter broad reach cvg group deliv revenu
ex-fx versu street diabet sale
ex-fx well ahead consensuss restor therapi group sale
organ versu street repres best quarter
franchis eight-year histori minim invas therapi group sale
ex-fx ex-divestitur versu street geograph
emerg market increas develop market increas us
western europ
takeaway elus oper leverag stori deliv oper
margin increas adjust flat
percentag revenu increas dollar basi increas
invest cvg diabet name renal denerv mitral valv
replac clinic trial advanc hybrid close loop diabet system
diabet deliv best quarter decad ex-fx well
ahead consensuss increas guidanc low-to-mid teen
low doubl digit intelli system strong start drive pain
stimul segment y/i increas continu
hot topic especi increas free cash flow manag shift
attent away product portfolio look tuck-in
manag increas revenu guidanc organ
comfort upper end rang fx headwind
versu reiter ep constant currenc
absorb fx shift increas pt base
ep estim
pleas refer page import disclosur includ analyst certif
therapi diabet franchis along
healthi cash flow dividend yield valuat
make compel invest
good sold
sale
 sale
chang incl fx impact
given steadi revenu growth rate combin
healthi cash flow dividend yield set price-to-earnings
multipl growth compani valu
product launch heart valv
segment expand respect market
face stiffer competit market
stent tavr market fail fulli captur
expect synergi relat covidien acquisit
usd
expect launch guardian connect
continu glucos monitor low-
risk approv tavr franchis data present
spring robot assist surgeri system
diversifi compani focus
cardiovascular spine neuromodul diabet
product includ icd pacemak diagnost
monitor devic electrophysiolog system
cardiovascular product includ coronari peripher
stent valv replac product stent graft
move show deliveri
firmli move show-m statu deliveri state
expect stock respond kind sever stop-and-go quarter deliveri realli
good revenu organ surpass street estim
highest growth rate sinc strength quarter broad reach
cvg group deliv revenu ex-fx versu street diabet
sale ex-fx well ahead consensuss restor therapi group
sale organ versu street repres best quarter
franchis eight-year histori minim invas therapi group sale ex-
fx ex-divestitur versu street geograph emerg market increas
develop market increas us western europ
importantli elus oper leverag stori deliv gross margin increas
pro forma y/i exclud impact fx oper margin flat underli basi
yet sg decreas significantli flat percentag
revenu increas dollar basi manag note increas invest
particularli cvg diabet name renal denerv mitral valv replac clinic
trial advanc hybrid close loop diabet system combin oper margin increas
adjust even ep better expect pro forma
ahead street oper fx tax relat final free
cash flow stark improv
compani first fiscal quarter earli year manag increas
revenu guidanc organ comfort upper end
revis rang fx headwind versu prior expect
reiter ep increas constant currenc ep growth fx
neutral ep versu benefit
guidanc revenu increas rel easi comp given
hurrican plu fx headwind impli slow
momentum expect continu throughout year manag repeatedli express
enthusiasm product portfolio face tougher y/i comp anniversari key
product launch price pressur certain geographi japan australia ep
guidanc rang versu consensuss absorb fx reiter
outperform
compani report factset streetaccount bmo capit market estim
exhibit guidanc
chang previou guidanc
tax rate expect /-
remaind fiscal year
chang previou guidanc
low- mid-teen
previous low-double-digit
compani report bmo capit market
chang previou guidanc constant
currenc growth rate increas
exhibit price-to-earnings multipl rel organ revenu growth rate
factset bmo capit market estim
diabet deliv best quarter decad ex-fx well ahead
consensuss manag increas guidanc low-to-mid teen low doubl
digit number factor drive franchis growth expect rate abat
near term first diabet market acceler new clinic data new product second
final gain traction us minim train activ
user ou sale mid-teen launch minim earli
commerci minim third guardian connect stand-alon cgm begin
penetr cgm market last least benefit transit johnson
johnson anima user minim devic manag note transit proceed
smoothli patient warranti suppli consum
anniversari outsid warranti work toward convert
pump manag convert least rate market share addit
put place program allow certain in-warranti patient anima pump
upgrad convert get compens manag report
gain six point market share quarter
launch intelli system strong start drive pain stimul
segment y/i increas strong intern growth even stronger growth
us intelli differenti competit market smaller footprint
evolv workflow result patient see real-world outcom similar clinic data
allow recaptur share accord market model estim us market
increas share rose y/i
interim real-world data intelli nan januari la vega
coronari structur heart anoth strong double-digit quarter driven high-teen growth
tavr double-digit growth resolut onyx onyx continu well us
manag comment approach all-tim high market share de busi tavr
continu steadi perform captur share europ japan driven global
expans evolut includ august launch japan launch enveo
deliveri system clinic side long-term data tavr platform present tct
septemb san diego includ five-year perform durabl data corevalv
two-year data surtavi real world result random savr lead american colleg
cardiolog meet march new orlean expect low-risk clinic data
spine franchis flat msd growth intern off-set lsd declin
us combin enabl technolog report neurosurgeri segment
manag note accur compar pure-play spinal compani sell implant
navig imag technolog sale increas manag still intend integr
consum sale strategi mazor robot highlight along
navig technolog nass septemb lo angel
free cash flow improv y/i driven oper effici
improv work capit although manag warn free cash flow
improv vari q/q pleas perform last two quarter maintain
full-year guidanc continu hot topic especi increas free
cash flow manag shift attent away product portfolio
first let take eye perform organ growth highest
return invest make supplement
focu tuck-in acquisit remain tuck-in acquisit
lot activ area continu monitor space right
opportun come along act activ complement
organ also import note like said earlier tuck-in
acquisit major focu size scale immedi
complement compani without benefit size scale
medtron rate histori
